Astria Therapeutics (NASDAQ:ATXS) Earns “Buy” Rating from HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $16.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 115.92% from the company’s previous close.

Separately, Oppenheimer boosted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Astria Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS opened at $7.41 on Thursday. The firm has a market capitalization of $418.15 million, a price-to-earnings ratio of -3.55 and a beta of 0.70. The business’s 50 day moving average price is $9.12 and its 200-day moving average price is $10.57. Astria Therapeutics has a 1 year low of $7.16 and a 1 year high of $16.90.

Hedge Funds Weigh In On Astria Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ATXS. China Universal Asset Management Co. Ltd. acquired a new stake in Astria Therapeutics in the 4th quarter valued at about $107,000. SG Americas Securities LLC lifted its position in Astria Therapeutics by 51.3% during the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock worth $190,000 after buying an additional 7,218 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Astria Therapeutics by 101.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company’s stock valued at $431,000 after buying an additional 19,735 shares in the last quarter. Barclays PLC grew its holdings in Astria Therapeutics by 70.5% in the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock valued at $1,020,000 after buying an additional 38,321 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Astria Therapeutics by 8.7% in the 3rd quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock worth $1,624,000 after acquiring an additional 11,763 shares during the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.